@article{5f7af7a8f30f4ea8a23f028ac648cb0b,
title = "Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211",
author = "Usmani, {S. Z.} and R. Sexton and S. Ailawadhi and Shah, {J. J.} and J. Valent and M. Rosenzweig and B. Lipe and Zonder, {J. A.} and S. Fredette and B. Durie and A. Hoering and B. Bartlett and Orlowski, {R. Z.}",
note = "Funding Information: SZU is a consultant for Celgene, Millennium, Onyx and Sanofi; RZO is a consultant and has received research funding for ArrayBioPharma, Bristol-Myers Squibb, Celgene, Janssen, Millennium, Onyx and Pharmacyclics; SA received honorarium from Millennium. JS is a consultant to Celgene, Millennium, Onyx and Novartis and has received research funding for ArrayBioPharma, Celgene, Millennium, Onyx and Novartis. JV has received speaking honoraria from Celgene and Millennium. The remaining authors declare no conflict of interest. This work was supported by NIH/NCI grants, CA180888, CA180819, CA180858, CA189971, CA189830, CA180835, CA180821, CA31946, CA21076, CA180799, CA21115, CA180820 and in part by Bristol-Myers Squibb Company and Celgene Corporation. Funding Information: This work was supported by NIH/NCI grants, CA180888, CA180819, CA180858, CA189971, CA189830, CA180835, CA180821, CA31946, CA21076, CA180799, CA21115, CA180820 and in part by Bristol-Myers Squibb Company and Celgene Corporation.",
year = "2015",
month = aug,
day = "14",
doi = "10.1038/bcj.2015.62",
language = "English (US)",
volume = "5",
journal = "Blood cancer journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "8",
}